Werewolf Therapeutics (NASDAQ:HOWL) Downgraded by Zacks Research to Hold

Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

HOWL has been the subject of a number of other research reports. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Werewolf Therapeutics Stock Up 1.9%

Shares of HOWL opened at $1.09 on Tuesday. Werewolf Therapeutics has a 52-week low of $0.27 and a 52-week high of $1.27. The company has a market capitalization of $52.97 million, a PE ratio of -1.43 and a beta of 0.55. The stock has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $0.69.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. StoneX Group Inc. boosted its position in shares of Werewolf Therapeutics by 174.3% during the third quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock worth $51,000 after buying an additional 34,856 shares during the period. Covestor Ltd acquired a new position in shares of Werewolf Therapeutics during the third quarter worth about $124,000. Vontobel Holding Ltd. acquired a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $55,000. Vilga Financial Planning LLC acquired a new position in shares of Werewolf Therapeutics during the third quarter worth $49,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at about $37,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.